Physician profile
Amina Rafique
NPI 1518197086
$10,836.10
in general payments reported to CMS, 2019-2025
24 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,040 · 2020: $1,899 · 2021: $2,617 · 2022: $94.70 · 2023: $49.42 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.35 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $7,302.90 | 2019-2020 | |
| Hema Biologics, LLC | $2,514.79 | 2021 | |
| Shire North American Group INC | $273.41 | 2019 | |
| Genzyme Corporation | $99.69 | 2020-2025 | |
| Novo Nordisk INC | $88.30 | 2019-2023 | |
| Genentech USA, INC. | $88.29 | 2019 | |
| Sobi, INC | $86.28 | 2019-2022 | |
| Genentech, INC. | $71.80 | 2025 | Hemlibra |
| Novartis Pharmaceuticals Corporation | $61.85 | 2019-2022 | |
| Eurofins Viracor, LLC | $35.64 | 2021 | |
| Emmaus Medical, INC. | $29.21 | 2019-2020 | |
| Amgen INC. | $23.06 | 2019 | |
| Biomarin Pharmaceutical INC. | $21.54 | 2021 | |
| Global Blood Therapeutics, INC. | $19.17 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.88 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.22 | 2020 | |
| Pfizer INC. | $17.15 | 2023 | |
| Medexus Pharma, INC. | $15.00 | 2021 | |
| Celgene Corporation | $14.79 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Tesaro, INC. | $11.80 | 2019 | |
| Dova Pharmaceuticals | $11.33 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Rafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.